Annual General Meeting of Q-Med AB (publ)

The Board of Directors of Q-Med AB (publ) (STO:QMED) has of today published a notice to attend the Annual General Meeting, which will be held on Tuesday April 29 at 3 p.m. on Q-Med's premises. Entrance from Fyrisvallsgatan 5, Uppsala, Sweden. A notice has been published in Upsala Nya Tidning, Svenska Dagbladet and in Post- och Inrikes Tidningar (Swedish Official Gazette). The complete notice of the Annual General Meeting in English can be found on the corporate web site www.q-med.com.

Q-Med AB (publ)

The Board

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane(R) for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux(R) for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta(TM) for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.

This information was brought to you by Cision http://newsroom.cision.com